JP2004521129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004521129A5 JP2004521129A5 JP2002567345A JP2002567345A JP2004521129A5 JP 2004521129 A5 JP2004521129 A5 JP 2004521129A5 JP 2002567345 A JP2002567345 A JP 2002567345A JP 2002567345 A JP2002567345 A JP 2002567345A JP 2004521129 A5 JP2004521129 A5 JP 2004521129A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- factor xiii
- administration
- additional therapeutic
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010071289 Factor XIII Proteins 0.000 claims description 11
- 229940012444 factor xiii Drugs 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims 2
- 208000027276 Von Willebrand disease Diseases 0.000 claims 2
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims 2
- 229960004281 desmopressin Drugs 0.000 claims 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims 2
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27046001P | 2001-02-21 | 2001-02-21 | |
| PCT/US2002/003742 WO2002067980A1 (en) | 2001-02-21 | 2002-02-07 | Method for treating von willebrand's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004521129A JP2004521129A (ja) | 2004-07-15 |
| JP2004521129A5 true JP2004521129A5 (https=) | 2008-11-20 |
Family
ID=23031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567345A Pending JP2004521129A (ja) | 2001-02-21 | 2002-02-07 | フォン・ヴィレブランド病の処理方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6979445B2 (https=) |
| EP (1) | EP1379271A1 (https=) |
| JP (1) | JP2004521129A (https=) |
| CA (1) | CA2438761A1 (https=) |
| WO (1) | WO2002067980A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101010333B (zh) | 2004-08-27 | 2013-08-14 | 诺和诺德医疗保健公司 | 从生物材料中纯化凝血因子xⅲ多肽 |
| EP2297330A4 (en) * | 2008-06-04 | 2012-03-14 | Bayer Healthcare Llc | FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND |
| US10172911B2 (en) | 2013-10-01 | 2019-01-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004505016A (ja) * | 2000-05-10 | 2004-02-19 | ノボ ノルディスク アクティーゼルスカブ | 第ＶＩＩａ因子及び第ＸＩＩＩ因子を含んで成る医薬組成物 |
-
2002
- 2002-02-07 EP EP02714852A patent/EP1379271A1/en not_active Withdrawn
- 2002-02-07 US US10/468,113 patent/US6979445B2/en not_active Expired - Fee Related
- 2002-02-07 JP JP2002567345A patent/JP2004521129A/ja active Pending
- 2002-02-07 CA CA002438761A patent/CA2438761A1/en not_active Abandoned
- 2002-02-07 WO PCT/US2002/003742 patent/WO2002067980A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1669364A3 (en) | Methods and compositions for treating hepatitis C virus | |
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| BR0316082A (pt) | Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit | |
| CA2594215A1 (en) | Sustained-release nanoparticle compositions and methods for using the same | |
| JP2004527551A5 (https=) | ||
| RU2005126412A (ru) | Сор1 для лечения воспалительных заболеваний кишечника | |
| JP2002532432A5 (https=) | ||
| EP1792915A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
| EP4667008A3 (en) | Methods and compositions for treating rna viral infections | |
| JP2005527547A5 (https=) | ||
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| JP2002528502A5 (https=) | ||
| JP2004537500A5 (https=) | ||
| RU2001132140A (ru) | Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин VI и его применение в фармацевтике | |
| RU2010153688A (ru) | Режим дозирования телапревира | |
| ATE491715T1 (de) | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten | |
| JP2003528919A5 (https=) | ||
| BR9809694A (pt) | Processo e composição para administração de taxanos oralmente a pacientes humanos | |
| DE69835435D1 (de) | Anti-arrhythmische zusammensetzungen und behandlungsverfahren | |
| JP2004521129A5 (https=) | ||
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| SE9902597D0 (sv) | New use | |
| WO2002058720A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
| KR960013383A (ko) | 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도 | |
| RU96120655A (ru) | Композиция для профилактики и лечения гриппа и орви |